• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.

    2/10/26 4:48:45 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KPTI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Karyopharm Therapeutics Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    48576U205

    (CUSIP Number)


    02/04/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    48576U205


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    997,577.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    997,577.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    997,577.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    48576U205


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,008,662.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,008,662.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,008,662.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    48576U205


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,008,662.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,008,662.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,008,662.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    48576U205


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,008,662.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,008,662.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,008,662.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.5 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Karyopharm Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    48576U205
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:02/09/2026
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:02/09/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:02/09/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:02/09/2026

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of February 9, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $KPTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KPTI

    DatePrice TargetRatingAnalyst
    2/5/2026Overweight
    Cantor Fitzgerald
    10/13/2025$15.00Neutral → Buy
    H.C. Wainwright
    7/16/2025Buy → Neutral
    H.C. Wainwright
    7/11/2025$27.00Buy
    H.C. Wainwright
    1/19/2023$8.00Overweight
    Piper Sandler
    11/4/2022$7.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    3/8/2022$12.00 → $8.00Sector Perform
    RBC Capital
    3/2/2022$8.00 → $6.00Market Perform
    SVB Leerink
    More analyst ratings

    $KPTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics

    Cantor Fitzgerald initiated coverage of Karyopharm Therapeutics with a rating of Overweight

    2/5/26 6:58:02 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Karyopharm Therapeutics from Neutral to Buy and set a new price target of $15.00

    10/13/25 8:40:25 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral

    7/16/25 7:54:08 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Karyopharm Therapeutics Inc.

    SCHEDULE 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    2/10/26 4:48:45 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    1/12/26 7:04:08 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Karyopharm Therapeutics Inc.

    DEF 14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)

    1/9/26 4:15:58 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    -- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to b

    2/5/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEWTON, Mass., Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of January 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three co

    2/2/26 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Preliminary Unaudited Full Year 2025 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $115 Million, Respectively – NEWTON, Mass., Jan. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2025 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2025 achievements and

    1/12/26 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Paulson Richard A. was granted 81,060 shares, increasing direct ownership by 41% to 279,391 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    2/9/26 4:11:58 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CFO & Treasurer Macomber Lori sold $10,244 worth of shares (1,626 units at $6.30), decreasing direct ownership by 2% to 85,105 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    2/4/26 4:11:52 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Commercial Officer Cheng Sohanya Roshan was granted 32,415 shares, increasing direct ownership by 41% to 111,921 units (SEC Form 4)

    4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)

    2/3/26 4:32:38 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Leadership Updates

    Live Leadership Updates

    View All

    Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

    NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow

    1/2/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

    NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi

    12/9/24 8:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

    NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t

    11/20/24 4:05:00 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Financials

    Live finance-specific insights

    View All

    Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    -- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to b

    2/5/26 7:30:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

    – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30,

    11/3/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

    -- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 27, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2025 financial results on Monday, November 3, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 3, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyo

    10/27/25 7:00:00 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KPTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/14/24 4:22:08 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/12/24 3:50:51 PM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Karyopharm Therapeutics Inc.

    SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)

    11/4/24 11:49:19 AM ET
    $KPTI
    Biotechnology: Pharmaceutical Preparations
    Health Care